New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling

Postgraduate Medical Journal

Volumn 84, Issue 993, 2008, Pages 348-353

  Wojciak Stothard, B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOVIRUS VECTOR; BOSENTAN; DIMETHYLARGININASE; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE INHIBITOR; SILDENAFIL; SIMVASTATIN;

BLOOD VESSEL TONE; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG TARGETING; GENE THERAPY; HUMAN; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE CONTRACTILITY;

ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; RHO GTP-BINDING PROTEINS;

EID: 50249084628     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.066555     Document Type: Review

References (81)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
2. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: expectation for rho-kinase inhibitors. Tohoku J Exp Med 2007;211:309-20.
3. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
4. Ito T, Ozawa K, Shimada K. Current drug targets and future therapy of pulmonary arterial hypertension. Curr Med Chem 2007;14:719-33.
5. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
6. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001; 114:2713-22.
7. Villalonga P, Ridley AJ. Rho GTPases and cell cycle control. Growth Factors 2006;24:159-64.
8. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
9. Liu HW, Halayko AJ, Fernandes DJ, et al. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol 2003;29:39-47.
10. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 2006; 16:522-9.
11. Kosako H, Goto H, Yanagida M. et al. Specific accumulation of Rho-associated kinase at the cleavage furrow during cytokinesis: cleavage furrow-specific phosphorylation of intermediate filaments. Oncogene 1999;18:2783-8.
12. Wennerberg K, Rossman KL, Oer CJ. The Ras superfamily at a glance. J Cell Sci 2005;118:843-6.
13. Wojciak-Stothard B, Ridley AJ. Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 2002;39:187-99.
14. Rolfe BE, Worth NF, World CJ, et al. Rho and vascular disease. Atherosclerosis 2005;183:1-16.
15. van Hinsbergh VW, van Nieuw Amerongen GP. Intracellular signalling involved in modulating human endothelial barrier function. J Anat 2002;200:549-60.
16. Tzima E. Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. Circ Res 2006;98:176-85.
17. Zhao XH, Laschinger C, Arora P, et al. Force activates smooth muscle alpha-actin promoter activity through the Rho signaling pathway. J Cell Sci 2007;120:1801-9.
18. Wojciak-Stothard B, Tsang LY, Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:L749-60.
19. Jaffa AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005;21:247-69.
20. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005;97:1232-5.
21. Loirand G, Guilluy C, Pacaud P. Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med 2006;16:199-204.
22. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem 2003;278:19023-31.
23. Mason JC. Statins and their role in vascular protection. Clin Sci (Lond) 2003;105:251-66.
24. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000;348(Pt 2):241-55.
25. Aktories K, Barbieri JT. Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol 2005;3:397-410.
26. Jones AT. Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm 2007;354:34-8.
27. van Watering S, van Buul JD, Quik S, et al. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J Cell Sci 2002;115:1837-46.
28. Haddad E, Zugaza JL, Louache F, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 2001;97:33-8.
29. Uehata M, Ishizaki T, Satoh H. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4.
30. Loge C, Wallez V, Scalbert E, et al. Rho-kinase inhibitors: pharmnacomodulations on the lead compound Y-32885. J Enzyme Inhib Med Chem 2002;17:381-90.
31. Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241:1033-40.
32. Harvey KA, Paranavitana CN, Zaloga GP, et al. Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation. J Cell Physiol 2007;211:353-63.
33. Narumrya S, Ishizaki T, Uehata M. Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol 2000;325:273-84.
34. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of local adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
35. Lampugnani MG, Zanetti A, Breviario F, et al. VE-cadherin regulates endothelial actin activating Rac and increasing membrane association of Tiam. Mol Biol Cell 2002;13:1175-89.
36. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57-62.
37. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000;87:526-8.
38. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000;275:21722-9.
39. Sauzeau V, Rolli-Derkinderen M, Marionneau C, et al. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003;278:9472-80.
40. Wojciak-Stothard B, Torondel B, Tsang LY, et al. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 2007;120:929-42.
41. Pak O, Aldashev A, Welsh D, et al. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007;30:364-72.
42. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-58.
43. Aaronson PI, Robertson TP, Knock GA, et al. Hypoxic pulmonary vasoconstriction: mechanisms and controversies. J Physiol 2006;570:53-8.
44. Mack CP, Somlyo AV, Hautmann M, et al. Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001;276:341-7.
45. Liu B, Itoh H, Louie 0. et al. The signaling protein Rho is necessary for vascular smooth muscle migration and survival but not for proliferation. Surgery 2002;132:317-25.
46. Shibata R, Kai H, Seki Y, et al. Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis. J Cardiovasc Pharmacol 2003;42(Suppl 1):S43-7.
47. Itoh Y, Kimoto K, Imaizumi M, et al. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 2007;84:464-72.
48. Yoneda A, Ushakov D, Multhaupt HA, et al. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and -II. Mol Biol Cell 2007;18:66-75.
49. Nishimura T, Vaszar LT, Faul JL. et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5.
50. McMurtry IF, Bauer NR, Fagan KA, et al. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol 2003;543:127-37.
51. Parker TA, Roe G, Grover TR, et al. Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am J Physiol Lung Cell Mol Physiol 2006;291:L976-82.
52. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 2007;91:283-90.
53. Haworth SG, Hall SM, Chew M, et al. Thinning of fetal pulmonary arterial wall and postnatal remodelling: ultrastructural studies on the respiratory unit arteries of the pig. Virchows Arch A Pathol Anat Histopathol 1987;411:161-71.
54. Haworth SG. Pulmonary hypertension in childhood. Eur Respir J 1993;6:1037-43.
55. Wojciak-Stothard B, Tsang LY, Paleolog E, et al. Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;290:L1173-82.
56. Bailly K, Ridley AJ, Hall SM, et al. RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. Circ Res 2004;94:1383-91.
57. Garcia JG, Liu F, Verin AD, et al. Sphingosine 1 -phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689-701.
58. Komarova YA, Mehta D, Malik AB. Dual regulation of endothelial junctional permeability. Sci STKE 2007;412:re8.
59. Robertson TP, Dipp M. Ward JP. et al. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 2000;131:5-9.
60. Wang J, Weigand L, Foxson J, et al. Ca2+ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. Am J Physiol Lung Cell Mol Physiol 2007;293:L674-85.
61. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-2.
62. Arrigoni Fl, Vallance P, Haworth SG, et al. Metabolism of asymmetric dimethylarginines is regulated in the lung developmental^ and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107:1195-201.
63. Millatt LJ, Whitley GS, Li D, et al. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 2003;108:1493- 8.
64. McMurtry MS, Bonnet S, Michelakis ED, et al. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007;293:L933-40.
65. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-76.
66. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005;127:1446-52.
67. Maclean MR, Johnston ED, McCulloch KM, et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-24.
68. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424- 8.
69. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002,137:1187-94.
70. Guilluy C, Sauzeau V, Rolli-Derkinderen M, et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005;146: 1010-8.
71. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
72. Homma N, Nagaoka T, Morio Y, et al. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 2007;50:697-702.
73. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-93.
74. Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656-64.
75. Li FH, Xia W, Li AW, et al. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin Med J (Engl) 2007;120:22-9.
76. Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-9.
77. McNamara PJ, Murthy P. Kantores C, et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am J Physiol Lung Cell Mol Physiol 2007:294:L205-13.
78. Hyvelin JM, Howell K, Nichol A, et al. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97:185-91.
79. Champion HC, Bivalacqua TJ, D'Souza FM, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res 1999;84:1422-32.
80. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96:442-50.
81. McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91.